Literature DB >> 1673996

L-phosphoserine, a metabolite elevated in Alzheimer's disease, interacts with specific L-glutamate receptor subtypes.

W E Klunk1, R J McClure, J W Pettegrew.   

Abstract

L-Phosphoserine is one of the phosphomonoesters elevated in Alzheimer's disease brain and has close structural similarity to L-glutamate. This study attempts to define precisely the actions of L-phosphoserine at L-glutamate receptor subtypes. L-Phosphoserine is shown to bind to N-methyl-D-aspartate and kainic acid receptor subtypes, but not to the quisqualic acid subtype. Studies of [3H]MK-801 binding in the presence and absence of L-glutamate and glycine show L-phosphoserine to be a competitive N-methyl-D-aspartate antagonist. The IC50 of L-phosphoserine in these studies varies from 373 to 721 microM. This may indicate a physiologically relevant action of L-phosphoserine in Alzheimer's disease brain because whole brain concentrations may reach over 1 mM.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673996     DOI: 10.1111/j.1471-4159.1991.tb03458.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  3 in total

1.  Group III metabotropic glutamate receptors as autoreceptors in the cerebellar cortex.

Authors:  Matthias Lorez; Urs Humbel; Marie-Claire Pflimlin; James N C Kew
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

2.  Searching for an endogenous anti-Alzheimer molecule: identifying small molecules in the brain that slow Alzheimer disease progression by inhibition of ß-amyloid aggregation.

Authors:  Autumn R Meek; Gordon A Simms; Donald F Weaver
Journal:  J Psychiatry Neurosci       Date:  2013-07       Impact factor: 6.186

3.  Meningioma phospholipid profiles measured by 31P nuclear magnetic resonance spectroscopy.

Authors:  L Seijo; T E Merchant; L T van der Ven; B D Minsky; T Glonek
Journal:  Lipids       Date:  1994-05       Impact factor: 1.880

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.